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ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine whether or not 
lenalidomide, in combination with dexamethasone, is a safe and effective treatment for relapsed 
multiple myeloma. 
STUDY DESIGN: Review of three English language primary trials published in 2007 and 2009. 
DATA SOURCES: Double blind, placebo-controlled, randomized clinical trials in which 
lenalidomide paired with dexamethasone was compared to placebo paired with dexamethasone 
were found utilizing Ovid MEDLINE and Cochrane databases  
OUTCOMES MEASURED: Time to progression, complete response, overall response, venous 
thromboembolism, and fatigue.  Time to progression, complete response, and overall response 
were all evaluated via  the European Group for Blood and Marrow Transplant response criteria.  
Incidence of venous thromboembolism and fatigue were evaluated via the National Cancer 
Institute’s Common Toxicity Criteria, version 2. 
RESULTS: In two of the studies, lenalidomide with dexamethasone was found to increase the 
time to progression of disease, complete response, and the overall response in comparison to the 
placebo plus dexamethasone in patients with relapsed multiple myeloma.  In the third study 
examined, lenalidomide with dexamethasone used in patients with only one prior therapy was 
found to increase the time to progression of disease, complete response, and the overall response 
in comparison to patients who had lenalidomide with dexamethasone with two or greater 
previous therapies.  In two of the studies, an increase in incidence of venous thromboembolism 
was noted in the lenalidomide with dexamethasone group in comparison to the placebo group.  
There was no association to be made between fatigue and lenalidomide with dexamethasone 
therapy. 
CONCLUSION: Lenalidomide with dexamethasone is an effective treatment to induce longer 
remissions for relapsed multiple myeloma patients.  The safety of lenalidomide with 
dexamethasone is jeopardized by increased incidence of venous thromboembolism, neutropenia 
and thrombocytopenia.  The combination therapy is not safe in respect to the patient’s overall 
health, but these dangers must be balanced against the more toxic drugs like thalidomide and the 
outcome of no treatment, which is quicker disease progression and death.  Future studies should 
evaluate lenalidomide with dexamethasone in patients who are newly diagnosed with no prior 
treatments. 
KEY WORDS: Lenalidomide, Dexamethasone, Relapsed Multiple Myeloma, Treatment, Safety 
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INTRODUCTION 
 Multiple myeloma is a malignancy of plasma cells that manifests as abnormalities and 
failure of the bone marrow, excessive production of monoclonal immunoglobulin (paraproteins), 
and bone destruction.  The bone marrow failure results in patients becoming 
immunocompromised, while the bone tumors (plasmacytomas) and subsequent bone destruction 
cause severe pain. High levels of paraproteins circulating commonly result in renal failure in 
multiple myeloma patients.
1,2,3
  Yearly incidence in the United States is about 4 people per 
100,000 and the median age at diagnosis is 68 years for multiple myeloma.
3 
 Diagnosis is made using the classic triad of bone marrow plasmacytosis > 10%, 
osteolytic lesions, and a serum and/or urine M (paraprotein) component that is determined via 
protein electrophoresis.
1,2,3
  Patients with multiple myeloma are treated first with induction 
therapy consisting of dexamethasone and either thalidomide or bortezomib or some combination 
of the two; after induction, patients under the age of 76 will usually undergo autologous 
hematopoietic stem cell transplantation for consolidation therapy.
1,2,3
 This two part treatment 
regimen is the gold standard. Since the exact etiology of multiple myeloma is unknown, a 
definitive cure for multiple myeloma has remained elusive; throughout this past decade, 
researchers and pharmaceutical companies have tried to find newer and possibly more effective 
and safer drugs, such as lenalidomide, which is a derivative of the parent compound, 
thalidomide.
4,5,6
  As of an article published in 2009, the cost to treat multiple myeloma patients 
with bortezomib was $3,504 after one year of treatment, while lenalidomide was $4,766 and 
thalidomide was $4,443.
7
  Other treatments than multiple myeloma-specific drugs were adjusted 
to cost around $3,907 for one year after diagnosis.
7
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 With cancer being the second most common cause of death in the United States, the 
treatment of multiple myeloma is relevant to a PA’s scope of practice, especially PAs employed 
in the hematology/oncology subspecialty, as well as primary care PAs.   
OBJECTIVE 
 The objective of this systematic review is to determine whether or not lenalidomide, in 
combination with dexamethasone, is a safe and effective treatment for relapsed multiple 
myeloma. 
METHODS 
 The three randomized, double-blind, phase III clinical control trials studied the 
subpopulation of multiple myeloma patients who were over the age of 18, had received one 
previous therapy for multiple myeloma, and also were in need of additional treatment at the time 
of enrollment in the trials.  The first trial evaluated, by Weber et al., had 353 participants enroll 
between February 23, 2003 to April 14, 2004, who met the abovementioned criteria, lived in the 
US or Canada, and had multiple myeloma sensitive to dexamethasone; patients had to be on 
greater than 200 milligrams in a previous treatment regimen without any progression of multiple 
myeloma during that time period to be considered dexamethasone-sensitive.  Participants were 
clinically diagnosed by having M protein serum levels of at least 0.5 gram/deciliter or a urinary 
Bence Jones protein level of at least 0.2 gram per day.  In addition, there were other eligibility 
criteria concerning patient’s immune status, and renal and hepatic levels of functioning.  The 
trial’s evaluation of responses to treatment was analyzed up until the trial was unblinded in June 
2005. 
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The second trial evaluated, by Dimopoulos et al., had 351 patients with enrollment 
between September 22, 2003 and September 15, 2004. The study had the exact same inclusion 
and exclusion criteria as the study done by Weber et al., with the one difference of only 
including patients who lived in Europe, Israel, or Australia.  The trial’s evaluation of response to 
the experimental treatment was analyzed up until the trial was unblinded in August 2005.  The 
third article by Stadtmauer et al., had 353 participants pooled from the two clinical trials by 
Weber et al. and Dimopoulos et al. and evaluated the specific subset of patients on lenalidomide 
with dexamethasone who had one previous therapy versus two or more previous therapies.   
The intervention evaluated in these three articles was oral lenalidomide 25 milligrams on 
days 1 through 21 of a 28-day cycle in combination with oral dexamethasone 40 milligrams on 
days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles.  After the fourth cycle, 40 milligrams 
of dexamethasone was administered only on days 1 to 4.  The experimental intervention was 
compared to a placebo pill distributed in conjunction with 40 milligrams of dexamethasone on 
days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and then after the fourth cycle, 40 
milligrams of dexamethasone was given on days 1 to 4. 
The outcomes assessed in the clinical trials were patient oriented objectives of time to 
progression (TTP), overall response (OR), and complete response (CR) for the patients being 
treated with multiple myeloma. A detailed search by the author utilizing the search engines Ovid 
MEDLINE and the Cochrane database was performed with the keywords of lenalidomide, 
Revlimid, and multiple myeloma.  All articles selected were published in peer-reviewed journals 
in the English language.  Articles for this systematic review were chosen if they reviewed 
randomized clinical control trial data, the treatment included lenalidomide plus dexamethasone, 
and patient-oriented evidence was analyzed.  Exclusion criteria included studies that only 
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evaluated lenalidomide alone as a treatment for multiple myeloma or studies that evaluated 
lenalidomide in conjunction with other drugs.  Statistics utilized in the studies included hazard 
ratio, p-value and confidence interval (CI). 
OUTCOMES MEASURED 
 The outcomes of interest in the clinical trials were patient oriented objectives of time to 
progression (TTP), complete response (CR), and overall response (OR) for the patients being 
treated with multiple myeloma. TTP is a measure of time after a disease is diagnosed (or treated) 
until the disease starts to advance.  The Weber et al. and Dimopoulos et al. articles delineated 
progression of multiple myeloma as an increase of at least 25% in M protein from lowest 
baseline, an absolute increase in serum M protein of greater than 500 milligrams per deciliter 
from lowest baseline, an absolute increase in urinary M protein of more than 200 milligrams per 
24-hour period, a new bone lesion (or increase in size of such lesions), and/or serum calcium 
level of more than 11.5 milligrams per deciliter.
4,6
  TTP, CR and OR were evaluated via the 
European Group for Blood and Marrow Transplant response criteria.  The articles by Weber et 
al. and Dimopoulos et al. defined CR as the complete disappearance of M protein in serum and 
urine by immunofixation and less than 5% marrow plasma cells.
4,6
    
Lastly, the OR takes into account patients who had a complete response in addition to 
patients with near-complete response and partial responses to therapy administered.  The criteria 
for near-complete and partial responses were identical in Weber et al. and Dimopoulos et al.  
Near-complete response was identical to those for complete remission but without confirmation 
of marrow plasma cells less than 5% or confirmation of disappearance of M protein in serum or 
urine via repeated immunofixation.
4,6
  Partial response was considered to be a reduction of M 
protein by at least 50% in serum, 90% in urine, or both.
4,6 
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Table 1- Demographics & Characteristics of Included Studies 
 
Secondary outcomes that were evaluated include side effects experienced by patients 
during the active treatment phase of the studies.  The incidence of venous thromboembolism and 
fatigue in both the experimental and control groups was noted out of the other adverse events 
reported because they were patient-oriented conditions.  Adverse side effects experienced during 
treatment were graded using the National Cancer Institute’s Common Toxicity Criteria, version 
Study Type Number 
of 
Patients 
Age (years) Inclusion 
criteria 
Exclusion 
criteria 
W/D Due 
to 
Toxicity 
Interventions 
Weber, USA 
and Canada, 
2007 
Double- 
blind, 
placebo-
controlled, 
phase III 
RCT 
353 36-86 
Median: 64 
for 
experime-
ntal group 
and 62 for 
placebo 
group 
Measura-
ble disease 
using 
standardi-
zed serum 
and/or 
urinary 
markers 
Disease that 
was 
considered 
resistant to 
dexameth-
asone; 
patients 
under 18 yo 
53 Patients 
randomized to 
receive either 
lenalidomide 
plus 
dexamethaso-
ne or placebo 
plus 
dexamethaso-
ne 
Dimopoulos, 
Europe, 
Israel and 
Australia, 
2007 
Double-
blind, 
plaebo-
controlled, 
phase III 
RCT 
351 33-82 
Median: 63 
for 
experime-
ntal group 
and 64 for 
placebo 
group 
Measura-
ble disease 
according 
to clinical 
criteria 
using 
serum 
and/or 
urinary 
markers 
Disease that 
was 
considered 
resistant to 
dexameth-
asone; 
patients 
under 18 yo 
31 Patients 
randomized to 
receive either 
lenalidomide 
plus 
dexamethaso-
ne or placebo 
plus 
dexamethaso-
ne 
Stadtmauer, 
international, 
2009 
Double-
blind, 
placebo-
controlled, 
RCT 
353 Median for 
1 therapy 
group was 
62.1 and for 
> 2 
therapies 
group was 
63.1 
 
Measura-
able 
disease 
according 
to clinical 
criteria 
using 
serum 
and/or 
urinary 
markers 
Patients 
that had 
never been 
treated for 
multiple 
myeloma; 
patients 
under 18 yo 
14.3% 
with 1 
therapy; 
14.5% in 
patients 
with > 2 
therapies 
Patients 
randomized to 
receive either 
lenalidomide 
plus 
dexamethaso-
ne or placebo 
plus 
dexamethaso-
ne 
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2.  In this systematic review, grade three (out of four) toxic effects for venous thromboembolism 
and fatigue were analyzed. 
RESULTS 
 In the three articles, the primary outcome of time to progression was presented as 
continuous data, while the rest of the primary and secondary outcomes analyzed in this review 
were presented in a dichotomous manner.  The studies employed an intention to treat analysis on 
all patients.  Sixty-eight patients in the lenalidomide group and 126 patients in the placebo group 
from the Weber et al. study were automatically discontinued from the study due to progression of 
their disease, while 35 patients in the lenalidomide group and 18 in the placebo group 
discontinued the study due to toxic effects from treatment.  Dimopoulos et al. article disclosed 
that patients were automatically discontinued from both the experimental and control groups due 
to progression of their disease.  Out of both the experimental and control groups, 31 patients 
stopped the study due to toxic effects from treatment. 
 In Weber et al., median time to progression, measured in months, was 11.1 in the 
lenalidomide plus dexamethasone (L&D) group and 4.7 in the placebo plus dexamethasone 
(P&D) group with a hazard ratio of 0.35 and a p-value < 0.001; hence, around one-third as many 
patients in the L&D group had disease progression at any point in time in the study compared to 
the placebo group.  In the Dimopoulos et al. article, the median time to progression, measured in 
months, was 11.3 and 4.7 in the L&D and P&D groups, respectively, with a hazard ratio of 2.85 
and a p-value < 0.001.  Therefore, patients in the P&D group had 2.85 times the likelihood of 
disease progression at any point in time in the study when compared to the L&D group. The 
Stadtmauer et al. study published a median time to progression, measured in months, of 17.1 in 
the lenalidomide with one previous therapy experimental group and 10.6 in the lenalidomide 
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with greater than or equal to two previous therapies comparison group and a hazard ratio of 0.68 
with a p-value = 0.026.  Hence, the Stadtmauer et al. study had around two-thirds as many 
patients in the lenalidomide with one previous therapy experimental group who experienced 
disease progression in comparison to the lenalidomide with two or greater previous therapies 
group. 
 Other primary results analyzed across all the three studies were complete response and 
overall response to treatment.  In the Weber et al. and Dimopoulos et al. studies, the L&D groups 
had 14.1% and 15.9% complete responses to the therapy, respectively.  The absolute benefit 
increase (ABI) for the lenalidomide plus dexamethasone treatment calculated from the Weber et 
al. study was 13.5% and the Dimopoulos et al. study had a similar computed ABI of 12.5%.  
Both studies evaluated would need to treat 8 patients with lenalidomide plus dexamethasone to 
achieve one complete response. 
Table 2- Efficacy of Lenalidomide in Terms of Time to Progression of Multiple Myeloma 
Disease Process in Experimental and Control/Comparison Groups 
Study Therapy Time to 
Progression 
Hazard Ratio 
(95% CI) 
p-value 
Weber 2007 L&D 11.1 0.35 P < 0.001 
 P&D 4.7 (0.27-0.47)  
Dimopoulos 
2007 
L&D 11.3 2.85 P < 0.001 
 P&D 4.7 (2.16-3.76)  
Stadtmauer 2009 L1 17.1 0.68 P = 0.026 
 L2+ 10.6 (0.48-0.97)  
For tables 2-5: L&D=lenalidomide plus dexamethasone; P&D=placebo plus dexamethasone; 
L1=lenalidomide plus dexamethasone in patients with one prior therapy; L2+=lenalidomide plus 
dexamethasone in patients with two or greater prior therapies; CI= confidence interval 
 In the Stadtmauer et al. article, the reported complete responses for the lenalidomide one 
previous therapy group and the lenalidomide two or greater previous therapies group were 20.3% 
and 11.8%, accordingly.  A relative benefit increase (RBI) in complete response of 72% was 
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found, as well as an ABI of 8.5%, in the lenalidomide one previous therapy group in comparison 
to the lenalidomide two or greater previous therapies group. A NNT of 12 was calculated 
meaning that 12 patients with one previous therapy would need to receive lenalidomide plus 
dexamethasone for one complete response to occur. 
The study by Weber et al. reported a statistically significant 61.0% overall response in the 
L&D group and 19.9% in the P&D group.  In the article by Dimopoulos et al., a statistically 
significant overall response of 60.2% was disclosed in the L&D group and 24.0% in the P&D 
group.  An ABI of 41.1% for the L&D group was determined in the Weber et al., while the ABI 
calculated for the Dimopoulos et al. L&D group was 36.2%.  Both of the studies had to treat 
three patients for one of them to achieve an overall response.  With the study by Stadtmauer et 
al., the lenalidomide with one previous therapy experimental group revealed a 66.9% overall 
response, while the comparison group had an overall response of 56.8%.  The reported p-value of 
0.060 is not considered statistically significant, but is in the range between 0.05 and 0.10, which 
indicates likelihood toward association of a higher effectiveness of lenalidomide in patients who 
have only had one previous therapy for multiple myeloma.  
 Secondary outcomes focused on adverse events experienced during treatment by patients 
and the possible association between the events and lenalidomide with dexamethasone treatment.  
The first adverse outcome to be analyzed was the incidence of venous thromboembolism (VTE) 
in participants of the studies.  The Weber et al. clinical trial had a statistically significant 
calculated absolute risk increase (ARI) of 11.3% for VTE in the L&D group.  The Dimopoulos et 
al. study had a computed statistically significant ARI of 4.0% for VTE in the L&D group.  The 
Stadtmauer et al. cinical trial did not have a statistically significant relationship between 
incidence of venous thromboembolism and the experimental one previous therapy group versus 
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the comparison two or greater previous therapies group.  The other adverse event evaluated 
across all three trials was fatigue.  A direct relationship between the study drugs of lenalidomide 
with dexamethasone and fatigue during the clinical trials cannot be drawn as is evident by the 
data in Table 5. 
Table 3- Efficacy of Lenalidomide in Terms of Complete Response in Experimental and 
Control/Comparison Groups 
Study Therapy Complete 
Response 
RBI ABI NNT p-value 
Weber 2007 L&D 25/177 
(14.1%) 
2250% 13.5% 8 P < 0.001 
 P&D 1/176 
(0.6%) 
    
Dimopoulos 
2007 
L&D 28/176 
(15.9%) 
367% 12.5% 8 P < 0.001 
 P&D 6/175 
(3.4%) 
    
Stadtmauer 
2009 
L1 27/133 
(20.3%) 
72% 8.5% 12 P=0.028 
 L2+ 26/220 
(11.8%) 
    
For tables 3 & 4: RBI=relative benefit increase; ABI=absolute benefit increase; NNT=numbers needed to 
treat 
Table 4- Efficacy of Lenalidomide in Terms of Overall Response in Experimental and 
Control/Comparison Groups 
Study Therapy Overall 
response 
RBI ABI NNT p-value 
Weber  
2007 
L&D 108/177(61.0%) 207% 41.1% 3 P< 0.001 
 P&D 35/176 (19.9%)     
Dimopoulos 
2007 
L&D  106/176 
(60.2%) 
151% 36.2% 3 P< 0.001 
 P&D 42/175 (24.0%)     
Stadtmauer 
2009 
L1 89/133 (66.9%) 17.8% 10.1% 10 P=0.060 
 L2+ 125/220 
(56.8%) 
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Table 5- Adverse Events Reported in Lenalidomide and Control/Comparison Groups 
Study Therapy Incidence of 
VTE 
NNH p-value Incidence 
of fatigue 
NNH p-value 
Weber 2007 L&D 26/177 (14.7%) 9 P < 0.001 11/177 
(6.2%) 
-1000 P < 0.001 
 P&D 6/175 (3.4%)   11/175 
(6.3%) 
  
Dimopoulos 
2007 
L&D  13/176 (7.4%) 25 P < 0.001 11/176 
(6.2%) 
36 P < 0.001 
 P&D 6/175 (3.4%)   6/175 
(3.4%) 
  
Stadtmauer 
2009 
L1  14/133 (10.5%) -55 P = 0.63 10/133 
(7.5%) 
-12 Not 
reported 
 L2+ 27/220 (12.3%)   13/220 
(15.9%) 
  
VTE=venous thromboembolism; NNH=numbers needed to harm; please note that the -55 means that 55 
patients should be treated in the L1 group to prevent one case of VTE and -1000/-12 means that 1000/12 
patients should be treated in L&D/L1, respectively, to prevent one case of fatigue 
DISCUSSION 
 Lenalidomide (Revlimid) plus dexamethasone is considered a treatment for multiple 
myeloma patients who have had at least one prior therapy regimen since the FDA approved it in 
mid-2006 due to the overwhelming results of the trials discussed in this systematic review.  
Lenalidomide is also FDA-approved for myelodysplastic syndrome patients.   Lenalidomide 
dosing amount and schedule is affected in patients with renal impairment.  Contraindications to 
the use of lenalidomide include hypersensitivity to the drug or any constituents in its 
formulation.  Boxed warnings issued by the FDA concern hematologic toxicity, 
thromboembolism and pregnancy.  Hematologic toxicity is exhibited in the majority of patients 
who are on lenalidomide in the forms of neutropenia and thrombocytopenia to the severity that 
complete blood counts (CBC) are routinely used in treatment regimens.  Lenalidomide has been 
correlated with a higher incidence of venous thromboembolism in patients on combination 
therapy with dexamethasone.  Finally, since lenalidomide is derived from the parent compound 
thalidomide, a known teratogen, pregnancy needs to be avoided in patients taking lenalidomide. 
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 The articles strictly studied the use of lenalidomide in combination with dexamethasone 
in patients who had one or more relapses of their multiple myeloma.  An obvious limitation to 
the studies was not evaluating if lenalidomide could be as effective in patients with newly 
diagnosed multiple myeloma without a history of treatment or relapse.  In the study of relapsed 
multiple myeloma, the patients averaged a greater amount of time since diagnosis than patients 
who are newly diagnosed.  Therefore, the relapsed patients were farther along in the natural 
disease progression and also had been exposed to more toxic treatments than newly diagnosed 
patients.  These factors in the study are a limitation to the overall efficacy of lenalidomide plus 
dexamethasone in preventing multiple myeloma disease progression and inducing complete and 
overall responses.   
CONCLUSION 
 Based on the data presented and calculated from the studies, lenalidomide with 
dexamethasone is an effective treatment to induce longer remissions than just dexamethasone 
alone in patients with relapsed multiple myeloma.  The efficaciousness of lenalidomide with 
dexamethasone was demonstrated through statistically significant longer time to progression of 
the disease state and higher complete and overall responses in comparison to placebo with 
dexamethasone.  The safety of lenalidomide with dexamethasone for patients is jeopardized by 
an increase in incidence of venous thromboembolism as well as other events not statistically 
represented in this analysis like neutropenia and thrombocytopenia.  In the future, randomized 
control trials should evaluate lenalidomide with dexamethasone in newly diagnosed patients 
without prior treatment to further assess the efficacy of this combination treatment in induction 
of remissions for multiple myeloma patients. 
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